Hosted on MSN20d
Pharmacy Benefit Managers Not Thrilled With FTC Report Finding Pharmacy Benefit Managers Raise Drug PricesThe pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen.
Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...
Hosted on MSN23d
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC SaysThe largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday.
The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...
After passing some regulations in 2024, Iowa state lawmakers are this year once again considering legislation that would further regulate pharmacy benefit managers — or PBMs.
The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback